JNJ - Vaxart: A Speculative Biotech With Potential As Covid-19 Play And Oral Vaccine Platform

• Results from the phase 2 study using the oral vaccine Covid-19 treatment is expected in the 1st half of 2022.
• Vaxart's oral vaccine technology is unique and holds great potential with several advantages like easier route of administration, room temperature stability, and greater potential ability to prevent transmission.
• An oral vaccine candidate being developed for norovirus holds potential to target a market worth up to $10 billion in the United States alone.
• An oral vaccine candidate being developed for influenza holds potential to target a market worth up to $5 billion in the United States alone.

For further details see: